tiprankstipranks
Advertisement
Advertisement
NeuroPace Earnings Call Highlights RNS Growth Momentum
PremiumCompany AnnouncementsNeuroPace Earnings Call Highlights RNS Growth Momentum
3M ago
NeuroPace: Buy Rating Reiterated on Raised Guidance, Differentiated RNS Platform, and Attractive $20 Price Target Versus High-Growth Med-Tech Peers
Premium
Ratings
NeuroPace: Buy Rating Reiterated on Raised Guidance, Differentiated RNS Platform, and Attractive $20 Price Target Versus High-Growth Med-Tech Peers
3M ago
NeuroPace reports Q1 EPS (20c), consensus (23c)
Premium
The Fly
NeuroPace reports Q1 EPS (20c), consensus (23c)
3M ago
NeuroPace: Strong 2025 Execution, Reimbursement Tailwinds, and Label Expansion Upside Support Reiterated Buy and $19 Target
PremiumRatingsNeuroPace: Strong 2025 Execution, Reimbursement Tailwinds, and Label Expansion Upside Support Reiterated Buy and $19 Target
5M ago
Regulatory Shutdowns Threaten Neuropace’s FDA Approvals and Capital Market Access
Premium
Company Announcements
Regulatory Shutdowns Threaten Neuropace’s FDA Approvals and Capital Market Access
5M ago
NeuroPace reports Q4 EPS (8c), consensus (17c)
Premium
The Fly
NeuroPace reports Q4 EPS (8c), consensus (17c)
5M ago
Morning Movers: L3Harris Technologies jumps after DoW investment
PremiumThe FlyMorning Movers: L3Harris Technologies jumps after DoW investment
7M ago
NeuroPace sees FY26 revenue $98M-$100M, consensus $98.44M
Premium
The Fly
NeuroPace sees FY26 revenue $98M-$100M, consensus $98.44M
7M ago
NeuroPace sees Q1 revenue $21M-$22M, consensus $22.35M
Premium
The Fly
NeuroPace sees Q1 revenue $21M-$22M, consensus $22.35M
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100